Product NDC: | 10144-594 |
Proprietary Name: | Zanaflex |
Non Proprietary Name: | tizanidine hydrochloride |
Active Ingredient(s): | 4 mg/1 & nbsp; tizanidine hydrochloride |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 10144-594 |
Labeler Name: | Acorda Therapeutics, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA020397 |
Marketing Category: | NDA |
Start Marketing Date: | 19970101 |
Package NDC: | 10144-594-15 |
Package Description: | 150 TABLET in 1 BOTTLE (10144-594-15) |
NDC Code | 10144-594-15 |
Proprietary Name | Zanaflex |
Package Description | 150 TABLET in 1 BOTTLE (10144-594-15) |
Product NDC | 10144-594 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | tizanidine hydrochloride |
Dosage Form Name | TABLET |
Route Name | ORAL |
Start Marketing Date | 19970101 |
Marketing Category Name | NDA |
Labeler Name | Acorda Therapeutics, Inc. |
Substance Name | TIZANIDINE HYDROCHLORIDE |
Strength Number | 4 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Adrenergic alpha2-Agonists [MoA],Central alpha-2 Adrenergic Agonist [EPC] |